|
Metin Tolan is a German physicist specializing in experimental physics with a focus on X-ray scattering and soft matter. He was born on 27 March 1965 in Oldenburg in Holstein, Germany. He studied physics and mathematics at Kiel University (Christian-Albrechts-Universität zu Kiel) from 1984 to 1989, where he received his doctorate in 1993 and later completed his habilitation. In 2001, he was appointed to the Chair of Experimental Physics I at TU Dortmund University. His research group applies methods of X-ray scattering and spectroscopy to investigate biological, chemical, and materials science questions. Prof. Tolan has received numerous awards for his outstanding scientific achievements and his commitment to science communication, including the Communicator Prize of the German Research Foundation (DFG). His research focuses on X-ray scattering, materials science, and the experimental physics of interfaces.
|
|
|
Aviv Regev is the head of Genentech Research and Early Development. Prior to Genentech, Regev served as Chair of the Faculty, Core Member, and Founding director of the Klarman Cell observatory at the Broad Institute of MIT and Harvard, and as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas. Regev has pioneered foundational experimental and computational methods in single-cell genomics, and is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and and disease. Among many honors, she is an elected member of the US National Academy of Sciences and National Academy of Medicine. |
|
|
Prof. Dr. Christof von Kalle, BIH Charité Professor Dr. med. Christof von Kalle has held the BIH Chair of Clinical Translational Sciences since June 2019 and is the founding director of the Clinical Study Center, an interdisciplinary and cross-campus platform of the Berlin Institute of Health (BIH) and Charité – Universitätsmedizin Berlin dedicated to the conduct of clinical studies. From 2019 to 2023, he was a member of the German Council of Experts for the Assessment of Developments in the Healthcare System (Sachverständigenrat Gesundheit, Federal Ministry of Health). From 2018 to 2019, Christof von Kalle served as Chief Research Officer at Sidra Medicine in Doha, Qatar. Previously, from 2005 to 2018, he was the founder and managing director of the National Center for Tumor Diseases (NCT) Heidelberg and Head of the Department of Translational Oncology at the German Cancer Research Center (DKFZ). From 2002 to 2005, he worked as Professor of Pediatrics in Cell and Gene Therapy at Cincinnati Children’s Hospital, Ohio, USA. He studied medicine in Cologne and New York and received his clinical and scientific training at the University of Freiburg and the Fred Hutch Cancer Center in Seattle, Washington. As a physician and scientist with a clinical background in hematology and oncology and more than 200 high-impact publications, he is an internationally recognized leading expert in stem cell research, mutation analysis, and gene transfer. Christof von Kalle has been awarded the Outstanding Achievement Award of the European Society for Gene and Cell Therapies (ESGCT). He is a co-founder of two successful biotech companies (Life Codexx, GeneWerk) and is known for initiating the NGO Vision Zero in Oncology, an alliance developing a novel paradigm to combat preventable cancer-related deaths. |
|
